One Case of Hepatic Injury Induced by Cefoperazone Sodium/Sulbactam Sodium for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection

Abstract

CLC Number:

R994.11

WEN Zhiyong, LU Wenfen. One Case of Hepatic Injury Induced by Cefoperazone Sodium/Sulbactam Sodium for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 253-254.

References

[1] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志,2015,31(11):1752-1768.
[2] Chalasani N P, Hayashi P H, Bonkovsky H L, et al.ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury[J]. The American Journal of Gastroenterology, 2014, 109(7):950-966.
[3] 江红接. 头孢哌酮舒巴坦钠致急性药物性肝损伤1例[J]. 肝脏,2014,19(1): 11.
[4] 唐莉,赵艳霞. 头孢哌酮舒巴坦钠致重症多形红斑型药疹合并肝损害1例[J]. 中国中西医结合皮肤性病学杂志,2010,9(2):123-124.
[5] 李冬云, 刘国树. 头孢哌酮钠/舒巴坦钠致严重肝功能损害[J]. 药物不良反应杂志, 2003, 5(1):47.
[6] 张斌,王楠,毛敏,等. 氟喹诺酮类药物致肝酶明显升高1例[J]. 中国药物警戒,2016,13(7):437-439.
[7] Nori S, Nebesio C, Brashear R, et al.Moxifloxacin-associated drug hypersensitivity synd- rome with toxic epidermal necrolysis and fulminant hepatic failure[J]. Archives of Dermatology, 2004, 140(12):1537-1538.
[8] 黄丽贞,雷光远,雷招宝. 莫西沙星致肝损害16例文献分析[J]. 药物流行病学杂志,2012,21(12):631-633.
[9] 贾王平,郭代红,田小燕,等. 79家医院1110例药物性肝损害不良反应/事件分析[J]. 中国药物警戒,2017,14(8):481-485.
[10] 徐焕春,乔逸,王婧雯. 注射用头孢哌酮钠/舒巴坦钠和盐酸莫西沙星片致严重肝损害[J]. 中国药物应用与监测,2013,10(2):121-122.
[11] 刘银萍,秦玉花,白楠,等. 莫西沙星在中国健康受试者体内的药代动力学研究[J]. 中国临床药理学杂志,2015,31(13):1255-1257.
[12] 吕晓菊. 注射用头孢哌酮钠/舒巴坦钠(2:1)的研发应用[J]. 中国医院药学杂志,2004,24(7):448.
[13] 何鑫, 刘丽华, 马红玲,等. 药物性肝损伤的临床药学监护[J]. 中国药师,2015,18(12):2107-2109.
[14] 尹小萍, 王辰. 临床药师对抗菌药物致急性药物性肝损伤的药学监护[J]. 中国医院用药评价与分析,2017(10):1434-1436.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.